STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.
Catherine M. Albert(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Catherine Lindgren(Unknown), Michael C. Jensen(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Nicholas A. Vitanza(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Wenjun Huang(Chengdu Research Base of Giant Panda Breeding), Prabha Narayanaswany(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Navin Pinto(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Christopher Brown, Juliane Gust(University of Washington), Vicky Wu(Fred Hutch Cancer Center), Erin R. Rudzinski(Indiana University School of Medicine)
Cited by 17
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754